Vitamin D

Of Vitamin D, and of the Quiet Governance It Exercises over Bone, Blood, and the Common Defence of the Body

A scholarly essay drawn from university studies of immunity, bone, genetic regulation, vitamin K2, mortality, sunlight, and the Hawaiian population

It is not unfitting, in an age that measures the hidden things of the blood with great precision, to consider a substance long known to sailors and bone-setters, yet only lately understood as a hormone that speaks to the genome itself. Vitamin D—more properly the family of secosteroids whose circulating marker is 25-hydroxyvitamin D, or 25(OH)D—arises chiefly from the skin under ultraviolet B light, is hydroxylated in the liver and again in the kidney (and, locally, in immune cells), and binds the vitamin D receptor (VDR). That receptor, paired with the retinoid X receptor, occupies vitamin D response elements across hundreds of loci. University laboratories have shown that this is not a narrow mineral clerk, but a regulator of calcium economy, innate and adaptive immunity, and the transcription of genes that govern proliferation, differentiation, and restraint of inflammation.

Serum 25(OH)D is here given throughout in nanograms per millilitre. The range of 50–100 ng/mL is a high band that some investigators have treated as optimal, though most large cohorts locate sufficiency nearer 20–30 ng/mL and observe a flattening of mortality risk well below 50 ng/mL.

Of bone, which is the first and most certain office of this hormone

The classical work of the vitamin D endocrine system is to keep the mineral budget of the skeleton. 1,25-dihydroxyvitamin D increases intestinal absorption of calcium and phosphate, suppresses excess parathyroid hormone, and coordinates osteoblast and osteoclast activity through VDR signalling. Without it, the growing skeleton yields rickets and the adult skeleton osteomalacia; with chronic insufficiency, fracture risk rises. Mutations that cripple the VDR produce early rickets and disordered mineral homeostasis—proof, as work from Rutgers and allied university groups has set out, that the ligand–receptor pair is not optional for skeletal order. Polymorphisms in VDR (FokI, BsmI, ApaI, TaqI) modestly alter receptor efficiency and have been linked, in university series, to differences in bone mineral density and fracture risk independent of circulating 25(OH)D.

Of vitamin K2, which does not finish the making of the hormone, yet finishes the work of the calcium it admits

It is sometimes said, in popular counsel, that vitamin K2 is required to convert the vitamin D precursor into the active hormone. That claim does not survive the biochemistry. Cholecalciferol made in the skin, or taken by mouth, is hydroxylated in the liver by CYP2R1 to 25(OH)D, and again by CYP27B1 in the kidney and in certain extra-renal cells to 1,25-dihydroxyvitamin D. Those enzymes, not menaquinone, complete the activation. Vitamin K2 is not a cofactor of that conversion.

What K2 does—and this is the partnership that university reviews rightly emphasise—is to make useful the proteins that active vitamin D calls into being. 1,25-dihydroxyvitamin D induces the transcription of osteocalcin in osteoblasts and of matrix Gla protein in vascular and other extrahepatic tissues. Those proteins remain inert until vitamin K, acting as cofactor for γ-glutamyl carboxylase, converts selected glutamate residues to γ-carboxyglutamate. Only then does osteocalcin bind hydroxyapatite and help to organise mineral in bone, and only then does matrix Gla protein restrain calcium deposition in arterial wall and soft tissue. Vitamin D, in short, writes the proteins; vitamin K2 signs them so that they may act.

There is a further, subtler cooperation. Work in cultured human osteoblasts has shown that 1,25-dihydroxyvitamin D can induce the epoxidase activity of the vitamin K cycle—the same carboxylase that activates osteocalcin—so that the active hormone not only raises the supply of the protein but also the cell’s capacity to carboxylate it when K2 is present. Menaquinone-4 may also serve as a ligand for the steroid and xenobiotic receptor in bone cells. Narrative reviews from European and other university groups therefore speak of synergy rather than of conversion: joint sufficiency of D and K appears more favourable to bone mineral density than vitamin D alone, and a 2020 meta-analysis of eight randomised trials (971 participants) found that combined vitamin K and vitamin D3 increased total bone mineral density. Evidence remains limited in scale, and not every trial agrees, yet the molecular logic is coherent.

A practical caution follows. Because vitamin D increases intestinal calcium absorption and the synthesis of undercarboxylated osteocalcin and matrix Gla protein, a rise in 25(OH)D without adequate vitamin K can, in principle, leave those proteins inactive and leave absorbed calcium less well directed. Whether that mechanism produces clinically important vascular calcification in ordinary supplementation is still debated; it is a reason to attend to K status—green leaves for phylloquinone, fermented foods and certain animal products for menaquinones—rather than a reason to treat K2 as the missing step in vitamin D activation itself.

Of the immune system, which is a second commonwealth within the first

Immune cells express VDR and can convert 25(OH)D to the active hormone on the spot. The genomic programme that follows is dual: it arms innate defence (cathelicidin and related antimicrobial peptides; tempered macrophage function) and cools adaptive excess (down-regulation of MHC-II and co-stimulatory molecules on dendritic cells; a shift away from unrestrained Th1 and Th17 activity toward regulatory tone). University reviews describe inhibition of NF-κB and NLRP3 inflammasome signalling and support of antioxidant programmes through Nrf2—mechanisms that make biological sense of the observational link between low 25(OH)D and worse outcomes in infection and autoimmunity, even while randomised trials of supplementation remain mixed once deficiency is no longer severe.

Of genetic regulation, which is the manner of the hormone’s speech

VDR occupies a wide chromatin landscape. Target networks include mineral transport, bone remodelling, detoxification, cell-cycle control, and immune transcription. Genome-wide association studies have mapped dozens of loci that influence circulating 25(OH)D itself—GC, CYP2R1, CYP24A1, DHCR7—so that heritability of status is substantial, and two persons under the same sun may not keep the same blood level. This genetic architecture is one reason sunlight, though necessary, is not a sufficient guarantee of any particular optimal range.

Of mortality, and of the numbers the cohorts yield

Observational epidemiology, which cannot of itself prove cause, is nonetheless consistent in direction. A meta-analysis of thirty-two studies found an all-cause mortality hazard ratio of about 1.9 comparing the lowest category of 25(OH)D (0–9 ng/mL) with the highest (greater than 30 ng/mL, and in a parallel contrast greater than 50 ng/mL). The pooled dose–response fell steeply up to roughly 30–39 ng/mL and appeared to plateau above about 50 ng/mL.

An individual-participant meta-analysis of 26,916 Europeans, using standardised 25(OH)D, took 30–40 ng/mL as reference. Adjusted hazard ratios for death were 1.15 at 16–20 ng/mL, 1.33 at 12–16 ng/mL, and 1.67 below 12 ng/mL. Risk did not rise meaningfully from 20 to 50 ng/mL, and the nadir lay near 31 ng/mL.

In the UK Biobank (365,530 participants free of major disease at baseline), mortality risk declined nonlinearly and levelled near 24 ng/mL for all-cause and cardiovascular death and near 18 ng/mL for cancer death. Those above these cut-points had about 17 percent lower all-cause, 23 percent lower cardiovascular, and 11 percent lower cancer mortality than those below.

EPIC-Norfolk, a University of Cambridge–linked cohort of 14,641 adults followed thirteen years, found age- and sex-adjusted hazard ratios for all-cause death of 0.84, 0.72, 0.71, and 0.66 across rising bands of 12–20, 20–28, 28–36, and 36 ng/mL or higher versus below 12 ng/mL. Fully adjusted, each increment of 8 ng/mL corresponded to about 8 percent lower mortality, with the lowest observed risk above 36 ng/mL and no signal of harm at the high end of the measured range.

A Danish registry analysis from the University of Copenhagen reported higher mortality below 20 ng/mL and above 40 ng/mL, with a preferred region near 28 ng/mL. Mayo Clinic data found higher mortality below 20 ng/mL in white patients, and no excess mortality above 50 ng/mL.

Taken together, university-based cohorts support a clear excess of death at frankly low 25(OH)D, a flattening of risk in the vicinity of 20–40 ng/mL, and little consistent evidence that 50–100 ng/mL is required to reach the mortality plateau. That higher band is sparsely populated in nature; few sun-exposed groups attain it, as the Hawaiian studies make plain.

Of the sun, which is the first laboratory

Ultraviolet B light photolyzes 7-dehydrocholesterol in the epidermis to previtamin D₃, which thermally isomerizes to vitamin D₃. Latitude, season, solar zenith angle, ozone, cloud, clothing, sunscreen, age (cutaneous 7-dehydrocholesterol declines with decades), and melanin all govern yield. Above about 35° latitude, winter ultraviolet B is often insufficient for synthesis. Darker pigmentation reduces, but does not abolish, production; traditional equatorial populations with high skin exposure can still achieve high 25(OH)D. The process is self-limited: prolonged ultraviolet B converts previtamin D₃ and vitamin D₃ into inactive photoproducts, so the skin does not manufacture without bound.

Of Hawaii, where the sun is plentiful and the blood is not always rich

Honolulu lies near 21°N; ultraviolet B is available the year round. Yet a collaboration of the University of Wisconsin and the University of Hawaii at Mānoa studied 93 healthy young adults who reported nearly twenty-nine hours of sun exposure per week. Mean 25(OH)D was 31.6 ng/mL; 51 percent stood below 30 ng/mL; the highest value recorded was 62 ng/mL. Hours of sun and skin colour did not tightly predict level. The authors concluded that responsiveness to ultraviolet B varies, and that abundant exposure does not guarantee even the 30 ng/mL threshold then under debate.

A later analysis from the Hawaii Longitudinal Study of Personality and Health (older adults, mean age about sixty) found a mean of 34.3 ng/mL; 38 percent were below 30 ng/mL despite a tropical climate. Supplement use and sun exposure raised levels; food intake did not explain the deficit; higher body-mass index and Asian or Native Hawaiian/Pacific Islander ancestry increased risk of insufficiency.

Thus the islands teach a sober lesson. If optimisation of immunity is defined as 50–100 ng/mL, sunlight alone—even persistent, near-equatorial sunlight—does not bring the ordinary body to that mark. The physiologic ceiling under habitual exposure commonly lies in the low-to-mid 30s ng/mL, with a minority approaching 60 ng/mL. If optimisation is defined by the mortality plateaus of the large cohorts, many Hawaiians still fall short of 30 ng/mL, and clothing, indoor life, adiposity, pigmentation, and genetic set-points explain why the sun’s office is incomplete.

A closing measure

Vitamin D is necessary to the architecture of bone, plausible as a modulator of innate readiness and adaptive restraint, and real as a transcription-factor ligand across a wide genome. Low circulating 25(OH)D is repeatedly associated with higher death; the association weakens once concentrations leave the deficient range. Vitamin K2 does not complete the hydroxylation of the precursor, yet it carboxylates the vitamin D–induced proteins that put absorbed calcium in bone and keep it from the vessel wall; the two vitamins are partners in use, not partners in activation. The sun remains the principal source of vitamin D, yet Hawaiian university studies show that even a people of abundant light do not, by light alone, reach the highest proposed targets. Wisdom would not despise the sun, nor pretend that nature has set every citizen’s blood at 50 ng/mL, nor confuse an observational curve with a completed proof of supplementation. It would measure the blood, correct true deficiency, mind vitamin K as well as D, tend the skeleton, and wait upon trials for the rest—lest we make an idol of a range the skin itself rarely grants.

Principal sources (university and consortium studies)

Garland et al., meta-analysis of all-cause mortality by serum 25(OH)D. Fan et al., UK Biobank, Journal of Clinical Endocrinology & Metabolism. Gaksch et al., European individual-participant meta-analysis, PLOS ONE. Khaw et al., EPIC-Norfolk, American Journal of Clinical Nutrition. Binkley, Novotny, Drezner et al., University of Wisconsin and University of Hawaii at Mānoa, Journal of Clinical Endocrinology & Metabolism (Hawaii sun-exposure cohort). Oshiro et al., Hawaii Longitudinal Study of Personality and Health. Christakos et al., Rutgers, vitamin D and bone. van Ballegooijen et al., synergistic interplay of vitamins D and K. Aaseth et al., Nutrients review of vitamins K and D for bone. Kuang et al., meta-analysis of combined K and D on bone mineral density. Miyake, Suhara and colleagues, 1,25-dihydroxyvitamin D3 and vitamin K2 metabolism in human osteoblasts. University reviews of VDR signalling, immunity, and genomic regulation.